Home > Publications Database > The NK1 antagonist L-733,060 facilitates sequence learning. > print

001     258691
005     20240112171645.0
024 7 _ |a pmc:PMC10291388
|2 pmc
024 7 _ |a 10.1177/02698811231161582
|2 doi
024 7 _ |a pmid:36988219
|2 pmid
024 7 _ |a 0269-8811
|2 ISSN
024 7 _ |a 1461-7285
|2 ISSN
037 _ _ |a DZNE-2023-00664
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Favila, Natalia
|0 P:(DE-2719)9001992
|b 0
|e First author
|u dzne
245 _ _ |a The NK1 antagonist L-733,060 facilitates sequence learning.
260 _ _ |a London [u.a.]
|c 2023
|b Sage
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1687870531_21788
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Although several brain regions and electrophysiological patterns have been related to sequence learning, less attention has been paid to the role that different neuromodulators play.Here we sought to investigate the role of substance P (SP) in sequence learning in an operant conditioning preparation, supported by a reinforcement learning model.Two experiments were performed to test the effects of an NK1 receptor (at which SP primarily acts) antagonist on learning and performing action sequences. In experiment 1, rats were trained to perform an action sequence until stable performance was achieved, and then, in phase 2, they were switched to perform the reverse sequence. In experiment 2, rats were trained to perform an action sequence, and in phase 2, they continued to do the same sequence. In both experiments in the first 3 days of phase 2, rats were injected with an NK1 receptor antagonist (L-733,060, i.p.) or with vehicle. Additionally, we developed a reinforcement learning model which allowed the in silico replication of our experimental tasks.We found that administering an NK1 receptor antagonist weakened the stable retention of a well-learned sequence, allowing the faster acquisition of a new sequence, without impairing the continued performance of a crystallized sequence. Using our reinforcement learning model, we suggest that SP could be acting through the state value learning rate, modulating the effects of the reward prediction error.Our results suggest that SP could be involved in the consolidation of a sequence representation through a modulatory effect on the reward prediction error.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Rats
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Learning
|2 MeSH
650 _ 2 |a Reinforcement, Psychology
|2 MeSH
650 _ 2 |a Piperidines: pharmacology
|2 MeSH
650 _ 2 |a Conditioning, Operant
|2 MeSH
650 _ 2 |a Reward
|2 MeSH
650 _ 2 |a Substance P: pharmacology
|2 MeSH
650 _ 2 |a Receptors, Neurokinin-1
|2 MeSH
650 _ 7 |a 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine
|0 148700-85-0
|2 NLM Chemicals
650 _ 7 |a Action sequences
|2 Other
650 _ 7 |a reinforcement learning
|2 Other
650 _ 7 |a reward prediction error
|2 Other
650 _ 7 |a striosomes
|2 Other
650 _ 7 |a substance P
|2 Other
650 _ 7 |a Piperidines
|2 NLM Chemicals
650 _ 7 |a Substance P
|0 33507-63-0
|2 NLM Chemicals
650 _ 7 |a Receptors, Neurokinin-1
|2 NLM Chemicals
700 1 _ |a Gurney, Kevin
|b 1
700 1 _ |a Overton, Paul G
|b 2
773 _ _ |a 10.1177/02698811231161582
|g p. 026988112311615 -
|0 PERI:(DE-600)2028926-1
|n 6
|p 610-626
|t Journal of psychopharmacology
|v 37
|y 2023
|x 0269-8811
856 4 _ |u https://journals.sagepub.com/doi/10.1177/02698811231161582
856 4 _ |u https://pub.dzne.de/record/258691/files/DZNE-2023-00664.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/258691/files/DZNE-2023-00664.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:258691
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001992
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2023-10-24
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J PSYCHOPHARMACOL : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-24
920 1 _ |0 I:(DE-2719)5000059
|k AG Krabbe ; AG Krabbe
|l Functional Diversity of Neural Circuits
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000059
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21